Feb 19 (Reuters) - Gilead Sciences Inc GILD.O :
* GILEAD RECEIVES APPROVAL IN CANADA FOR YESCARTA™ (AXICABTAGENE CILOLEUCEL) CAR T THERAPY FOR ADULTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA AFTER TWO OR MORE LINES OF SYSTEMIC THERAPY
* GILEAD SCIENCES INC - YESCARTA IS NOT INDICATED FOR TREATMENT OF PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA